Hengrui Medicine (01276.HK) reported net profit attributable to shareholders of approximately RMB 6.923 billion for the first three quarters, up 20.38% year on year.

Zhitong Finance APP News: Hengrui Pharmaceuticals (01276.HK) announced its results for the first three quarters of 2026, with revenue of approximately RMB 24.409 billion, up 5.26% year on year; net profit attributable to shareholders of the listed company of approximately RMB 6.923 billion, up 20.38% year on year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB 6.243 billion, up 11.70% year on year; and basic earnings per share of RMB 1.05. The company continued to increase its innovation efforts and maintained a high level of R&D investment. In the first three quarters of 2026, the company's cumulative R&D investment amounted to RMB 7.146 billion, of which RMB 5.423 billion was expensed R&D investment.